Isolation, analytical measurements, and cell line studies of the iron–bryostatin-1 complex. Issue 10 (15th May 2016)

• Record Type: Journal Article
• Authors: Plummer, Sydney; Manning, Thomas; Baker, Tess; McGreggor, Tysheon; Patel, Mehulkumar; Wylie, Greg; Phillips, Dennis
• Is Part Of: Bioorganic & medicinal chemistry letters. Volume 26:Issue 10(2016)
• Page Start: 2489
• Page End: 2497
• Publication Date: 2016-05-15
• Subjects: Bryostatin -- Synthesis -- Cancer -- Cell line -- Iron -- Aquaculture -- Candidatus Endobugula sertula -- Bugula neritina; Bioorganic chemistry -- Periodicals; Pharmaceutical chemistry -- Periodicals; 572
• DOI: 10.1016/j.bmcl.2016.03.099
• Languages: English
• ISSNs: 0960-894X

Abstract

Graphical abstract: Bryostatin-1 is a marine natural product that has demonstrated medicinal activity in pre-clinical and clinical trials for the treatment of cancer, Alzheimer's disease, effects of stroke, and HIV. In this study, iron–bryostatin-1 was obtained using a pharmaceutical aquaculture technique developed by our lab that cultivates marine bacteria for marine natural product extraction. Analytical measurements 1 H and 13 C NMR, mass spectrometry, and flame atomic absorption were utilized to confirm the presence of an iron–bryostatin-1 complex. The iron–bryostatin-1 complex produced was then tested against the National Cancer Institute's 60 cell line panel. Adding iron to bryostatin-1 lowered the anti-cancer efficacy of the compound. Abstract: Bryostatin-1 is a marine natural product that has demonstrated medicinal activity in pre-clinical and clinical trials for the treatment of cancer, Alzheimer's disease, effects of stroke, and HIV. In this study, iron–bryostatin-1 was obtained using a pharmaceutical aquaculture technique developed by our lab that cultivates marine bacteria for marine natural product extraction. Analytical measurements 1 H and 13 C NMR, mass spectrometry, and flame atomic absorption were utilized to confirm the presence of an iron–bryostatin-1 complex. The iron–bryostatin-1 complex produced was then tested against the National Cancer Institute's 60 cell line panel. Adding iron to bryostatin-1 lowered the anti-cancer efficacy of the compound.